Evidence map›Paper›PMID 40534993›Full record

ArticleJTO clinical and research reports2025

Erratum to 'Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100815].

Federico Cappuzzo, Zanete Zvirbule, Ernesto Korbenfeld, Jaroslaw Kolb-Sielecki, Dolores Isla, Aleksandra Szczesna, Amparo Yovanna Castro Sanchez, Alberto Bustillos, Xiaoyan Liu, Fiona Young and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Subcutaneous immunotherapy as a catalyst for decentralized, oncologist-led cancer care: a mixed-methods analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Federico CappuzzoIRCCS Regina Elena National Cancer Institute, Rome, Italy.
Zanete ZvirbuleRiga Eastern Clinical University Hospital, Riga, Latvia.
Ernesto KorbenfeldHospital Británico de Buenos Aires, Buenos Aires, Argentina.
Jaroslaw Kolb-SieleckiWarmian-Masurian Center of Pulmonary Diseases, Olsztyn, Poland.
Dolores IslaUniversity Hospital Lozano Blesa, Zaragoza, IIS Aragon, Spain.
Aleksandra SzczesnaMazowieckie Centrum Leczenia Chorób Płuc Gruźlicy, Otwock, Poland.
Amparo Yovanna Castro SanchezF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Alberto BustillosF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Xiaoyan LiuGenentech, Inc., South San Francisco, California.
Fiona YoungF. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom.
Nadia TostiF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Marta Freitas MonteiroF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Margarita MajemHospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.jtocrr.2025.100815.].

Identifiers

PMID40534993
PMCPMC12172275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.